SuperworthLexaria Bioscience revenue LEXX
Sales by quarter and over the last twelve months, from 2010.
- Last 12 months, to May 31, 2026
- $194K
- Latest quarter, Q3 FY26
- $0
- −100% on a year earlier
- Fiscal year 2025
- $705.9K
- +52% on the year before
Lexaria Bioscience's revenue was $194K over the twelve months to May 31, 2026, down 69% on a year earlier.
In its latest quarter, Q3 FY26, it was $0, down 100% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 37% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $705.9K | +52% |
| FY2024 | $464.3K | +105% |
| FY2023 | $226.2K | −11% |
| FY2022 | $255.4K | −65% |
| FY2021 | $722.7K | +387% |
| FY2020 | $148.3K | −33% |
| FY2019 | $222.6K | −49% |
| FY2018 | $433.3K | +581% |
| FY2017 | $63.6K | +56% |
| FY2016 | $40.7K | +177% |
| FY2015 | $14.7K | n/a |
| FY2014 | n/a | n/a |
| FY2014 | n/a | n/a |
| FY2013 | $1.1M | −19% |
| FY2012 | $1.4M | +20% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $0 | −100% | $194K | |
| Q2 FY26 | $20K | −89% | $368K | |
| Q1 FY26 | $0 | −100% | $522K | |
| Q4 FY25 | $174K | +107% | $705.9K | |
| Q3 FY25 | $174K | +107% | $615.9K | |
| Q2 FY25 | $174K | +20% | $525.9K | |
| Q1 FY25 | $183.9K | +22% | $496.9K | |
| Q4 FY24 | $84K | +173% | $464.3K | |
| Q3 FY24 | $84K | +8% | $411K | |
| Q2 FY24 | $145K | +624% | $404.7K | |
| Q1 FY24 | $151.3K | +55% | $279.8K | |
| Q4 FY23 | $30.7K | −72% | $226.2K |
Against its peers
Companies in Healthcare nearest Lexaria Bioscience's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| LEXXLexaria Bioscience | $194K | −69% a year |
| OXBROXBRIDGE RE HOLDINGS | $2.8M | +40% a year |
| EDUCEducational Development | $20M | −32% a year |
| GTIMGood Times Restaurants | $135.1M | −6% a year |
| MDRRMedalist Diversified | $9.6M | −1% a year |
| BCGBinah Capital | $191.9M | +8% a year |
| VIPVulcan Infrastructure & Power | $50.9M | −14% a year |
| MXCMexco Energy | $6.7M | −9% a year |
| CKXCKX Lands | $693.4K | −17% a year |
| MSGMMotorsport Games | $14.5M | +79% a year |
| ATCHAtlasClear | $20.1M | +85% a year |
| Peer median | $17.3M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Lexaria Bioscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.